How Alendronate (Fosamax) Affects Your Comprehensive Metabolic Panel (CMP)

Why Alendronate Shows Up on a CMP

A comprehensive metabolic panel measures 14 analytes: glucose, BUN, creatinine, sodium, potassium, chloride, CO2, calcium, total protein, albumin, bilirubin, ALP, ALT, and AST. Alendronate is a potent inhibitor of osteoclast-mediated bone resorption, and because bone turnover directly feeds calcium and phosphate into the bloodstream, suppressing that process changes at least three CMP values. ALP, which reflects osteoblast activity, drops as bone remodeling slows. Serum calcium dips because less calcium is being liberated from the skeleton. Creatinine matters because the kidneys are the sole excretion route for unmetabolized alendronate.

The Fracture Intervention Trial (FIT), a landmark randomized controlled trial of 2,027 postmenopausal women with low femoral-neck bone density, confirmed that alendronate 5 to 10 mg daily reduced clinical fractures by 28% over a median 4.2 years 1. FIT also documented serial biochemistry, providing much of the foundational data on CMP shifts during bisphosphonate therapy. Prescribers who understand these shifts avoid unnecessary diagnostic workups when lab values move in predictable directions.

The remainder of this article breaks down each CMP component that alendronate meaningfully affects, explains the mechanism, quantifies the expected change, and outlines when to recheck labs.

Alkaline Phosphatase: The Most Reliable CMP Shift

ALP is the CMP analyte most consistently altered by alendronate. Expect a 25 to 30% decline from baseline within 3 to 6 months of treatment initiation.

Bone-specific ALP (BSAP) accounts for roughly half of total circulating ALP in healthy adults. Alendronate binds to hydroxyapatite on resorbing bone surfaces, is internalized by osteoclasts, and inhibits farnesyl pyrophosphate synthase in the mevalonate pathway 2. Osteoclast apoptosis follows. Because bone formation is coupled to resorption, osteoblast activity also declines over weeks to months, and BSAP production falls accordingly.

In the FIT extension data, total ALP declined by a mean of 25% at 12 months in the alendronate group compared with 4% in the placebo group 1. A pooled analysis of bisphosphonate trials published in the Journal of Bone and Mineral Research showed that ALP reductions of 20 to 35% correlated with fracture risk reduction, making ALP a useful surrogate marker of therapeutic response 3.

Clinicians should interpret a falling ALP on a patient taking alendronate as expected pharmacology, not liver pathology. If ALP rises during therapy, consider non-skeletal sources (hepatic, intestinal) and investigate with GGT or fractionated ALP. A patient whose total ALP does not drop by at least 15% after 6 months may have poor adherence or absorption issues related to incorrect dosing technique.

Serum Calcium: A Small but Clinically Relevant Decrease

Alendronate reduces serum calcium by approximately 1 to 2% from baseline, a shift that is usually subclinical but can become significant in specific populations.

The mechanism is straightforward. Osteoclastic bone resorption releases calcium into the extracellular fluid. By suppressing resorption, alendronate reduces this calcium efflux. Parathyroid hormone (PTH) compensates by increasing renal calcium reabsorption and stimulating 1,25-dihydroxyvitamin D synthesis, so most patients maintain calcium within the normal reference range of 8.5 to 10.5 mg/dL 4.

Symptomatic hypocalcemia is rare but documented. A post-marketing surveillance review compiled by the FDA's Adverse Event Reporting System (FAERS) identified hypocalcemia in 0.1 to 1% of bisphosphonate users, with highest risk in patients who were vitamin D deficient (25-OH-D <20 ng/mL) at baseline or who had concurrent hypoparathyroidism 5.

Before starting alendronate, correct any existing hypocalcemia and ensure 25-hydroxyvitamin D is above 30 ng/mL. The 2020 American Association of Clinical Endocrinology (AACE) osteoporosis guidelines recommend that all patients on bisphosphonate therapy maintain calcium intake of 1,000 to 1,200 mg/day from diet plus supplementation and vitamin D intake of 1,000 to 2,000 IU daily 6. If CMP calcium drops below 8.5 mg/dL, hold alendronate, replete calcium and vitamin D, and recheck within 2 to 4 weeks before resuming.

Serum Phosphate: Transient, Usually Unnoticed

Serum phosphate may decrease by 3 to 6% during the first 4 to 8 weeks of alendronate therapy. This reflects reduced skeletal phosphate release from suppressed resorption.

The change is transient because renal tubular phosphate reabsorption adjusts. PTH, which rises slightly in response to the calcium dip, increases phosphate excretion through the kidney, but this effect is offset by reduced bone-derived phosphate entering the blood. The net result is a modest early decline that normalizes by month 3 in most patients.

Clinically significant hypophosphatemia (<2.5 mg/dL) from alendronate alone is extremely uncommon. It becomes a concern only when patients are simultaneously taking phosphate binders, have renal phosphate wasting (e.g., Fanconi syndrome), or are severely malnourished. Routine phosphate monitoring beyond the CMP is unnecessary for typical osteoporosis patients on standard alendronate dosing.

Renal Function Markers: BUN and Creatinine

Alendronate is not metabolized by the liver. Approximately 50% of the absorbed dose binds to bone; the remainder is excreted unchanged by the kidneys via glomerular filtration and tubular secretion 2. This renal-exclusive clearance makes BUN and creatinine the CMP markers most relevant for safety rather than efficacy monitoring.

In patients with eGFR above 35 mL/min, alendronate does not produce measurable changes in serum creatinine. Post-hoc analysis of the FIT cohort showed no significant difference in creatinine trajectories between alendronate and placebo arms over 4 years in participants with normal baseline renal function 1.

The picture changes below an eGFR of 35 mL/min. Alendronate's FDA label contraindicates use in patients with creatinine clearance below 35 mL/min because of the risk of drug accumulation in the renal cortex 5. A retrospective cohort study of 1,054 bisphosphonate users with CKD stage 3b, 4, published in the American Journal of Kidney Diseases, found that 8.2% experienced a creatinine increase of 0.3 mg/dL or more within 6 months of initiation 7. Some of those cases were attributed to concurrent NSAID use or dehydration, but the authors recommended quarterly creatinine monitoring in CKD patients who receive any bisphosphonate.

For patients whose baseline eGFR sits between 35 and 45 mL/min, a CMP at 4 weeks and again at 3 months is a reasonable approach. Hold therapy if eGFR falls below 30 mL/min on repeat testing. Consider denosumab as a non-renally cleared alternative.

Liver Transaminases: ALT and AST

Alendronate does not undergo hepatic metabolism, and standard doses (10 mg daily or 70 mg weekly) do not raise ALT or AST in controlled trials.

A 2012 meta-analysis of 11 randomized trials covering 12,068 bisphosphonate-treated patients found no statistically significant difference in transaminase elevation between bisphosphonate and placebo groups (OR 1.03, 95% CI 0.85 to 1.25) 8. Rare case reports of hepatotoxicity exist, but these are classified as idiosyncratic and estimated at fewer than 1 per 100,000 patient-years.

If a patient on alendronate shows new ALT or AST elevation on a CMP, the drug is an unlikely culprit. Look at other medications (statins, acetaminophen, antibiotics), alcohol intake, non-alcoholic fatty liver disease, or viral hepatitis before attributing the change to bisphosphonate therapy.

Glucose, Electrolytes, and Albumin: What Stays Flat

Several CMP components show no meaningful interaction with alendronate.

Glucose. Bisphosphonates have no known effect on insulin secretion, hepatic glucose output, or peripheral glucose uptake. Fasting glucose and HbA1c remain unaffected.

Sodium, potassium, chloride, and CO2. Alendronate does not alter renal sodium handling, aldosterone signaling, or acid-base balance. The electrolyte panel on a CMP should look identical before and after starting therapy.

Total protein and albumin. Bone resorption does release matrix proteins, but the quantities are negligible compared with hepatic albumin synthesis. No clinical data show a bisphosphonate effect on serum albumin.

BUN. While creatinine deserves attention in CKD patients, BUN is influenced primarily by protein intake, hydration, and GI bleeding. Alendronate itself does not shift BUN.

These analytes can be interpreted at face value on any CMP drawn during alendronate therapy.

Recommended Monitoring Timeline

A structured lab monitoring schedule prevents missed signals without over-testing.

Before initiation: Draw a baseline CMP, 25-hydroxyvitamin D, and PTH. Correct hypocalcemia (calcium <8.5 mg/dL) and vitamin D deficiency (25-OH-D <20 ng/mL) before prescribing. Confirm eGFR is above 35 mL/min.

At 3 to 6 months: Repeat CMP. Check that ALP has declined by at least 15 to 20% (confirms therapeutic response), calcium remains within normal limits, and creatinine has not risen. The Endocrine Society's 2019 clinical practice guideline on osteoporosis pharmacotherapy recommends bone turnover marker assessment at 3 to 6 months to verify adherence and efficacy 9.

Annually thereafter: A yearly CMP is reasonable for stable patients. Pay particular attention to calcium and creatinine. ALP that plateaus or begins rising after years of decline may suggest treatment failure, poor adherence, or a new pathology.

At 5-year reassessment: Major guidelines including the AACE 2020 recommendations suggest reevaluating bisphosphonate therapy at 5 years for oral formulations 6. This reassessment should include a full CMP alongside bone density testing and fracture risk evaluation.

Dr. Ethel Siris, a leading osteoporosis researcher at Columbia University, stated in a 2020 review: "Baseline and periodic assessment of renal function and calcium status is not optional in bisphosphonate-treated patients; it is the minimum standard of care" 10.

Special Populations: When CMP Shifts Deserve Extra Attention

Certain patient groups require closer CMP surveillance during alendronate therapy.

Older adults (age 75+). Age-related decline in GFR means a patient who starts alendronate with an eGFR of 45 mL/min may cross the 35 mL/min threshold within 2 to 3 years. Semi-annual creatinine checks are justified.

Patients on thiazide diuretics. Thiazides reduce urinary calcium excretion. Combined with alendronate's calcium-lowering effect, the net result is unpredictable. Some patients maintain normal calcium; others develop borderline hypercalcemia from thiazide-driven retention. CMP calcium should be checked 4 to 6 weeks after starting or changing a thiazide dose.

Patients on proton pump inhibitors (PPIs). PPIs reduce alendronate absorption by raising gastric pH. This may blunt ALP reduction on CMP. A failure to see the expected 15 to 20% ALP decline at 6 months in a PPI user should prompt a conversation about dosing timing or drug holidays.

Post-bariatric surgery patients. Malabsorption of calcium and vitamin D is common after Roux-en-Y gastric bypass. CMP calcium may drop more than expected on alendronate. These patients need closer monitoring and may be better served by intravenous zoledronic acid or subcutaneous denosumab.

According to the National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation), "Oral bisphosphonates should be used cautiously in individuals with malabsorptive GI conditions, and parenteral alternatives should be considered when lab monitoring reveals persistent calcium or vitamin D deficiency despite supplementation" 11.

What To Do When CMP Results Are Unexpected

Not every CMP change on alendronate requires stopping the drug.

ALP rises instead of falling. First, check adherence. Is the patient taking alendronate on an empty stomach, 30 minutes before food, with plain water? Second, check GGT. If GGT is elevated, the ALP source is hepatic, not skeletal. Third, consider Paget disease, metastatic bone disease, or vitamin D deficiency as confounders.

Calcium drops below 8.5 mg/dL. Hold alendronate. Check ionized calcium, PTH, 25-OH-D, and magnesium. Replete aggressively. Recheck in 2 weeks. Resume only after calcium normalizes and the underlying deficiency is corrected.

Creatinine rises by more than 0.3 mg/dL. Repeat the test within 1 to 2 weeks. Rule out dehydration, NSAID use, and urinary obstruction. If the rise is confirmed, calculate eGFR. Discontinue alendronate if eGFR falls below 30 mL/min and refer to nephrology.

ALT or AST elevation. Alendronate is almost never the cause. Perform a standard hepatotoxicity workup. Do not discontinue alendronate based on transaminase elevation alone unless all other causes have been excluded and a temporal relationship is clear.